为您找到相关结果约500个

你是不是要搜索 期刊ABC-01 is a worldwide, randomized, placebo-controlled with active treatment, parallel-group, multi-site, double-blind trial of IV ABC combined with carboplatin- paclitaxel/nab-paclitaxel chemotherapy versus saline placebo combined with carboplatin-paclitaxel/nab-paclitaxel chemotherapy in subjects with metastatic squamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for metastatic disease.'A=0 点击跳转

Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatmentsfor Chinese, treatment-naive, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective

Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumabin Patients With Metastatic Squamous Non-Small-Cell Lung Cancer

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Nab-paclitaxel maintenance therapy following carboplatin plus nab-paclitaxel combination therapy in chemotherapynaive patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase IItrial

An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With NecitumumabVersus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-CellLung Cancer

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxeland gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE

Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxelfor non-squamous non-small cell lung cancer with malignant pleural effusion

Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completelyresected non-small-cell lung cancer: FAST-nab

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxelfor Advanced/Metastatic Non-Small Cell Lung Cancer

Efficacy and Adverse Reactions of Carboplatin, Nab-Paclitaxel Regimen Combined with Atezolizumab in theTreatment of Non-Small Cell Lung Cancer

Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung CancerReceiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin

Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-smallcell lung cancer (NSCLC).

A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatmentof patients with stage IV squamous non-small cell lung cancer

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors inrelapsed small-cell lung cancer

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled

为您找到相关结果约500个

共500条页码: 1/34页15条/页